Ifenprodil
Chemical compound
From Wikipedia, the free encyclopedia
Ifenprodil, sold under the brand names Cerocral, Dilvax, and Vadilex, is a cerebral vasodilator that has been marketed in some countries, including in Japan, Hong Kong, and France.[1][2][3][4] It is currently under development for treatment of a variety of additional indications.[5]
| |
| Clinical data | |
|---|---|
| Trade names | Cerocral, Dilvax, Vadilex |
| Other names | NP-120; NP 120; NP120; RC 61-91 |
| Drug class | Cerebral vasodilators; NMDA receptor antagonists |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.041.341 |
| Chemical and physical data | |
| Formula | C21H27NO2 |
| Molar mass | 325.452 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ifenprodil has multiple known pharmacological actions.[5] It is an inhibitor of the NMDA receptor,[6] specifically of NMDA receptors containing GluN1 and GluN2B subunits, the "ifenprodil binding site".[7] Additionally, ifenprodil inhibits GIRK channels[8] and interacts with α1-adrenergic,[5] serotonin,[9] and sigma receptors.[10][11][12][5]
Chemically, ifenprodil is a substituted phenethylamine and β-hydroxyamphetamine derivative.[2][3] It is used pharmaceutically as the tartrate salt.[1][2][3]
Research
Ifenprodil has been studied as a possible medication to prevent tinnitus after acoustic trauma.[13]
It is currently in phase II trials for cough and idiopathic pulmonary fibrosis, among other investigational uses.[5]
See also
- Traxoprodil (another β-hydroxyamphetamine NMDA receptor antagonist)